CINCINNATI--(BUSINESS WIRE)--Oct. 31, 2018--
Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company
focused on developing compounds that activate Tie2 to treat ocular
diseases and diabetic complications, today announced that its third
quarter 2018 financial results will be released before the market opens
on Wednesday, November 7, 2018. Following the release, the Company will
host a live conference call and webcast at 8:30 a.m. EST to discuss the
Company’s financial results and provide a general business update.
The live webcast and a replay may be accessed by visiting Aerpio's
website at http://ir.aerpio.com/.
Please connect to the Company's website at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that may
be needed to access the webcast. Alternatively, please call (877)
216-7943 (U.S.) or (417) 629-5045 (international) to listen to the live
conference call. The conference ID number for the live call is 4090026.
Please dial in approximately 10 minutes prior to the call. Telephone
replay will be available approximately two hours after the call. To
access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406
(international). The conference ID number for the replay is 4090026.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on
advancing first-in-class compounds that activate Tie2 to treat ocular
diseases and complications of diabetes. Tie2 is an important regulator
of vascular stability and its down-regulation is found in patients with
diabetes. Down-regulation is caused by activation of two inhibitors of
Tie2, VE-PTP and Ang-2 due to hypoxia or tissue ischemia. The Company’s
lead compound, AKB-9778, is a systemically-administered small molecule
activator of the Tie2 pathway (via highly selective and potent
deactivation of VE-PTP) and is in clinical development for the treatment
of non-proliferative diabetic retinopathy. AKB-9778 is also being
investigated for its potential utility in treating diabetic nephropathy
and an eyedrop formulation is in development as a potential treatment
for open-angle glaucoma. For more information, please visit www.aerpio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181031005216/en/
Source: Aerpio Pharmaceuticals, Inc.
Investors & Media:
McClellan, on behalf of Aerpio Pharmaceuticals, Inc.
Steinberg / Robert Flamm, Ph.D.